Co-Expression of Programmed Death-Ligand 1 (PD-L1) Expression in EGFR Mutant Stage IV Lung Adenocarcinoma

被引：0
|
作者：
Hsu, P. [1 ]
Wang, C. [2 ]
Kuo, S. [3 ]
Yang, C. [4 ]
机构：
[1] Chang Gung Med Fdn, Taoyuan, Taoyuan County, Taiwan
[2] Chang Gung Med Fdn, Dept Pathol, Taoyuan, Taoyuan County, Taiwan
[3] Chang Gung Med Fdn, Dept Thorac Med, Taoyuan, Taoyuan County, Taiwan
[4] Chang Gung Mem Hosp, Taoyuan, Taiwan
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A7292
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    LABORATORY INVESTIGATION, 2017, 97 : 344A - 344A
  • [22] Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor
    Suteau, Valentine
    Collin, Alexandre
    Menei, Philippe
    Rodien, Patrice
    Rousselet, Marie-Christine
    Briet, Claire
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (10) : 2053 - 2061
  • [23] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    MODERN PATHOLOGY, 2017, 30 : 344A - 344A
  • [24] PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma
    Isobe, Kazutoshi
    Kakimoto, Atsushi
    Mikami, Tetuo
    Kaburaki, Kyohei
    Kobayashi, Hiroshi
    Yoshizawa, Takahiro
    Nakano, Yuta
    Makino, Takashi
    Otsuka, Hajime
    Sano, Go
    Sugino, Keishi
    Sakamoto, Susumu
    Takai, Yujiro
    Tochigi, Naobumi
    Iyoda, Akira
    Homma, Sakae
    ONCOLOGY REPORTS, 2018, 40 (01) : 331 - 338
  • [25] Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells
    Arrieta, O.
    Cruz-Rico, G.
    Aviles-Salas, A.
    Popa-Navarro, X.
    Flores-Velez, K. Y.
    Ramirez-Tirado, L.
    Vergara, E.
    Barron, F.
    Cabrera-Miranda, L. A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S162 - S162
  • [26] Difference Of Programmed Death-Ligand 1 Expression In Subtypes Of Adenocarcinoma Of The Lung
    Son, C.
    Roh, M. -S.
    Choi, P. -J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [27] Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma
    Gulec, Umran Kucukgoz
    Bagir, Emine Kilic
    Paydas, Semra
    Guzel, Ahmet Baris
    Gumurdulu, Derya
    Vardar, Mehmet Ali
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2020, 244 : 51 - 55
  • [28] Programmed Cell Death Ligand 1 (PD-L1) Expression in Pancreatic Ductal Adenocarcinoma
    Sheffield, Brandon S.
    Kalloger, Steve E.
    Milne, Katy
    Nelson, Brad H.
    Renouf, Daniel
    Schaeffer, David F.
    MODERN PATHOLOGY, 2016, 29 : 200A - 200A
  • [29] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN TYPE 2 ENDOMETRIAL CANCER
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1127 - 1127
  • [30] Programmed Cell Death Ligand 1 (PD-L1) Expression in Pancreatic Ductal Adenocarcinoma
    Sheffield, Brandon S.
    Kalloger, Steve E.
    Milne, Katy
    Nelson, Brad H.
    Renouf, Daniel
    Schaeffer, David F.
    LABORATORY INVESTIGATION, 2016, 96 : 200A - 200A
12345